ja_mageia

NEUROFIBROMATOSIS CLINICAL RESEARCH AWARDS: CALL FOR LETTERS OF INTENT

The Children’s Tumor Foundation announces a call for Letters of Intent for Clinical Research Awards of up to $100,000.  The Clinical Research Awards seek broad-thinking, novel ideas  to conduct pilot clinical trials of candidate therapeutics for the treatment of tumors and other manifestations of NF1, NF2 and schwannomatosis; OR innovative studies ancillary or adjunct to clinical trials that - if successful - will contribute to the advancement of effective clinical therapies for neurofibromatosis.

Examples of projects encouraged may include but are not limited to:
-    Biomarker studies adjunct to an ongoing clinical trial (may be e.g. molecular, imaging or genetic biomarkers, or other novel outcome parameters) that may better inform on and ultimately help accelerate a clinical trial.
-    Preclinical/clinical collaborative studies (‘clinical co-trials’). Note however that all studies must include a clinical element – preclinical-only studies are not eligible.
-    Applications to fund pilot neurofibromatosis clinical trials are welcomed an encouraged.

Click here to download the Clinical Research Award Request for Applications

2011 Funded Clinical Trial Awards
 

Phase II Trial of Rapamycin - NF2 Tumors
Dr. Matthias Karajannis, New York University Langone Medical Center

New metrics for optic pathway glioma trials
Dr. Robert Avery, Children’s National Medical Center

Blood predictors of NF1 severity
Dr. Cynthia Hingtgen, Indiana University

Computerized ‘maze’ for NF1 learning disabilities trials
Dr. Nicole Ullrich, Children’s Hospital Boston


2009 Funded Clinical Trial Awards

Phase 0 Trial of Tykerb (Lapatinib) for NF2 Vestibular Schwannoma
Principal Investigators: Dr. Jaishri Blakeley (Johns Hopkins University) and Dr. Matthias Karajannis (New York University Langone Medical Center)
Collaborating Sites: Ohio State University, and the House Ear Institute. GlaxoSmithKline is providing the drug as well as technical support for the study.  

Phase I Trial of Nexavar (Sorafenib) for NF1 Plexiform Neurofibroma
Principal Investigators: Dr. Bruce Korf (University of Alabama at Birmingham), Dr. Aerang Kim and Dr. Brigitte Widemann at (NIH-NCI)  
Collaborating site: Children’s Hospital of Philadelphia